Melinta Therapeutics, Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, an antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Vabomere, a carbapenem used in treatment of gram-negative infections; Orbactiv, an antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens, as well as Solithromycin, a macrolide antibiotic for the treatment of CABP. The company also develops Baxdela that in a Phase III clinical trial for treating community-acquired bacterial pneumonia (CABP)); Fusidic Acid, which is in Phase III clinical trial for treating ABSSSIs; and radezolid, a melinta molecule that is in Phase II clinical trial for dermatological applications, as well as ESKAPE pathogen program, which is in preclinical stage targeting superbugs. Melinta Therapeutics, Inc. was formerly known as formerly Rib-X Pharmaceuticals, Inc. and changed its name to Melinta Therapeutics, Inc. in October 2013. The company was founded in 2000 and is headquartered in New Haven, Connecticut.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:MLNT
Previous Symbol
CUSIP15130J10
Phone908-617-1309
Debt
Debt-to-Equity Ratio0.46
Current Ratio1.34
Quick Ratio1.04
Price-To-Earnings
Trailing P/E Ratio-0.05
Forward P/E Ratio-0.32
P/E GrowthN/A
Sales & Book Value
Annual Sales$33.86 million
Price / Sales1.95
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.31 per share
Price / Book0.51
Profitability
EPS (Most Recent Fiscal Year)($21.86)
Net Income$-58,910,000.00
Net Margins-202.31%
Return on Equity-68.68%
Return on Assets-32.84%
Miscellaneous
Employees300
Outstanding Shares56,020,000
Market Cap$68.90 million
OptionableOptionable
Melinta Therapeutics (NASDAQ:MLNT) Frequently Asked Questions
What is Melinta Therapeutics' stock symbol?
Melinta Therapeutics trades on the NASDAQ under the ticker symbol "MLNT."
How were Melinta Therapeutics' earnings last quarter?
Melinta Therapeutics Inc (NASDAQ:MLNT) released its quarterly earnings data on Wednesday, November, 7th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.55. The biotechnology company earned $34.08 million during the quarter, compared to the consensus estimate of $17.24 million. Melinta Therapeutics had a negative net margin of 202.31% and a negative return on equity of 68.68%. View Melinta Therapeutics' Earnings History.
When is Melinta Therapeutics' next earnings date?
What price target have analysts set for MLNT?
7 equities research analysts have issued 12 month target prices for Melinta Therapeutics' shares. Their predictions range from $8.00 to $15.00. On average, they anticipate Melinta Therapeutics' stock price to reach $12.5833 in the next year. This suggests a possible upside of 948.6% from the stock's current price. View Analyst Price Targets for Melinta Therapeutics.
What is the consensus analysts' recommendation for Melinta Therapeutics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Melinta Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Melinta Therapeutics.
What are Wall Street analysts saying about Melinta Therapeutics stock?
Here are some recent quotes from research analysts about Melinta Therapeutics stock:
- 1. LADENBURG THALM/SH SH analysts commented, "We are transferring coverage of Melinta Therapeutics, maintaining our Buy rating and $14.00 price target. Melinta is an antibiotics company with four marketed products in the for acute bacterial skin and skin structure infections (ABSSSI), Vabomere for complicated urinary tract infections and Minocin IV for several serious infections (see pages 2-3 for details). Additional candidates are also in development for several indications (see Exhibit 1). With scaled back launch expectations, we believe Vabomere and Baxdela (launched January 2018, respectively) can reach more modest consensus estimates and represents an attractive value currently." (12/18/2018)
- 2. According to Zacks Investment Research, "Melinta Therapeutics, Inc. develops and commercializes novel antibiotics designed to provide new and better therapeutic solutions. Melinta's lead product is Baxdela, an antibiotic approved by the US FDA for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta also has an extensive pipeline of preclinical and clinical stage products that were developed internally or assumed under the 2017 acquisition of Cempra, Inc. This pipeline includes many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Melinta is headquartered in New Haven, CT. " (11/2/2018)
- 3. HC Wainwright analysts commented, "We note that Orbactiv is already approved by the EMA, whereas a MAA has yet to be filed for Minocin. While we await an 8-K filing for more details on the financial terms of this agreement, we point to three more near-term milestones for MLNT: (1) seven posters and one oral presentation later this week at Francisco (we are in attendance for the full duration); (2) sales and prescription trends from the 3Q18 results expected in early the pivotal Phase 3 data for Baxdela in community-acquired bacterial pneumonia (CABP) before year end. Affirm Buy." (10/2/2018)
- 4. Cantor Fitzgerald analysts commented, "We expect sales of key drugs (such as to exceed consensus expectations. Therefore, upwards earnings revisions should drive MLNT’s stock higher, in our view. Valuation Summary We use a blend of P/E and DCF analysis to arrive at our $15 PT. The Disclosure Section may be found on pages 3 – 5.Valuation We use a blend of P/E and DCF analysis to arrive at our $15 PT." (8/3/2018)
Has Melinta Therapeutics been receiving favorable news coverage?
News stories about MLNT stock have trended positive on Wednesday, InfoTrie reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Melinta Therapeutics earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the next few days.
Who are some of Melinta Therapeutics' key competitors?
Some companies that are related to Melinta Therapeutics include Kadmon (KDMN), MannKind (MNKD), BIOFRONTERA AG/ADR (BFRA), Seres Therapeutics (MCRB), Dova Pharmaceuticals (DOVA), Intec Pharma (NTEC), Savara (SVRA), Verrica Pharmaceuticals (VRCA), Arbutus Biopharma (ABUS), Athersys (ATHX), BioDelivery Sciences International (BDSI), Catalyst Pharmaceuticals (CPRX), Adamas Pharmaceuticals (ADMS), AVEO Pharmaceuticals (AVEO) and Syros Pharmaceuticals (SYRS).
Who are Melinta Therapeutics' key executives?
Melinta Therapeutics' management team includes the folowing people:
- Dr. Erin M. Duffy Ph.d., Chief Scientific Officer (Age 50)
- Mr. John H. Johnson, Interim CEO & Director (Age 60)
- Dr. Thomas A. Steitz Ph.D., Co-Founder
- Dr. Peter B. Moore Ph.D., Co-Founder
- Dr. William L. Jorgensen Ph.D., Co-Founder
Who are Melinta Therapeutics' major shareholders?
Melinta Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (5.13%), BlackRock Inc. (4.33%), Stonepine Capital Management LLC (3.50%), Stonepine Capital Management LLC (3.50%), Vanguard Group Inc. (3.16%) and Vanguard Group Inc (3.16%). Company insiders that own Melinta Therapeutics stock include David N Gill, Dov A Md Goldstein, Paul Estrem, Sue Cammarata and Vatera Healthcare Partners Llc. View Institutional Ownership Trends for Melinta Therapeutics.
Which major investors are selling Melinta Therapeutics stock?
Which major investors are buying Melinta Therapeutics stock?
MLNT stock was acquired by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Stonepine Capital Management LLC, BlackRock Inc., Sphera Funds Management LTD., JPMorgan Chase & Co., JPMorgan Chase & Co., First Manhattan Co. and Dimensional Fund Advisors LP. Company insiders that have bought Melinta Therapeutics stock in the last two years include David N Gill, Paul Estrem, Sue Cammarata and Vatera Healthcare Partners Llc. View Insider Buying and Selling for Melinta Therapeutics.
How do I buy shares of Melinta Therapeutics?
Shares of MLNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Melinta Therapeutics' stock price today?
One share of MLNT stock can currently be purchased for approximately $1.20.
How big of a company is Melinta Therapeutics?
Melinta Therapeutics has a market capitalization of $68.90 million and generates $33.86 million in revenue each year. The biotechnology company earns $-58,910,000.00 in net income (profit) each year or ($21.86) on an earnings per share basis. Melinta Therapeutics employs 300 workers across the globe.
What is Melinta Therapeutics' official website?
How can I contact Melinta Therapeutics?
Melinta Therapeutics' mailing address is 300 GEORGE STREET SUITE 301, NEW HAVEN CT, 06511. The biotechnology company can be reached via phone at 908-617-1309 or via email at [email protected]
MarketBeat Community Rating for Melinta Therapeutics (NASDAQ MLNT)
MarketBeat's community ratings are surveys of what our community members think about Melinta Therapeutics and other stocks. Vote "Outperform" if you believe MLNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MLNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
